The Office of the U.S. Trade Representative plans to decide in about two weeks whether to continue dispute-settlement discussions with the European Union over its failure to lift its de facto moratorium on the sale of U.S. biotechnology products, a U.S. trade official said April 2. Discussions with the EU over the issue were held at the end of February, the official said, ”to assess the seriousness of their intentions” to normalize trade.